Developed by Jere Segrest, M.D., director of the Atherosclerosis Research Unit at the University of Alabama, Atherotech’s patented VAP Test provides direct, detailed measurements of the lipid subclasses that cause cardiovascular disease. The profiles obtained by the test also allow physicians to create individualized treatment plans while continuing to track patients’ progress in battling heart disease.
Atherotech, a Birmingham, Alabama-based provider of cardiometabolic testing services that offers the VAP (Vertical Auto Profile) advanced lipid profile test, has been acquired by private equity investment firm Behrman Capital.
The equity capital for the acquisition, which closed on December 23, 2010, came from Behrman Capital IV L.P., while debt financing was provided by MidCap Financial.
In conjunction with the transaction, Robert Flaherty, an Operating Partner at Behrman Capital, will serve as Chairman of the company’s board of directors.
Led by CEO Michael Mullen, Atherotech provides its services to physicians, hospitals, clinics, and other laboratories throughout the United States.
Commenting on the acquisition, Grant G. Behrman, Managing Partner of Behrman, said: “We look forward to partnering with and the rest of the Atherotech management team as they continue to pursue the growth of their business”.